Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

Thomas C. Krivak, MD, shares the positive results from the RUBY trial of pembrolizumab plus chemotherapy followed by maintenance in patients with dMMR advanced endometrial cancer, supporting its approval and use in this population.

Related Content:

Recent Advances in Treating Endometrial and Cervical CancersGynecologic OncologyOncLive Peer Exchange®

Clinical Considerations for 2L Treatment Sequencing in mCRC

Overview of Molecular Testing and Barriers in mCRC

ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC